Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
Gilead Sciences, Inc. (Nasdaq: GILD) and Tubulis today announced that they have entered into an exclusive option and license ...
pharmaphorum7h
Gilead looks beyond Trodelvy with Tubulis alliance
The deal with Tubulis gives Gilead access to the German biotech's ADC technology platform, designed to make ADCs more stable, ...
News Medical13d
Novel fluoroquinolone analogs as anticancer agents
These compounds are specifically designed to inhibit the Topoisomerase II enzyme, a critical player in DNA replication and ...
BioWorld27d
AVA-6103 for the treatment of FAP-positive cancer by targeting topoisomerase
Avacta Life Sciences (Avacta Group plc) presented preclinical data on AVA-6103, a second-generation Precision peptide-drug conjugate, being developed for the potential treatment of cancer. AVA-6103 ...